Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 8/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542555 | 1.00 | PIK3CB (0.44) | PIK3CBABCB1PARP1HRH1 | |
| SCHEMBL4529997 | 1.00 | PIK3CB (0.44) | PIK3CBABCB1PARP1HRH1 | |
| SCHEMBL29475045 | 1.00 | PIK3CB (0.44) | PIK3CBABCB1PARP1HRH1 | |
| SCHEMBL4537899 | 0.94 | PIK3CB (0.43) | PIK3CBABCB1HRH1 | |
| SCHEMBL4541825 | 0.93 | PIK3CB (0.43) | PIK3CBABCB1HRH1 | |
| SCHEMBL4533089 | 0.91 | PIK3CB (0.40) | PIK3CBABCB1HRH1 | |
| SCHEMBL4538785 | 0.90 | PIK3CB (0.46) | PIK3CBHRH1 | |
| SCHEMBL4538790 | 0.90 | PIK3CB (0.46) | PIK3CBHRH1 | |
| SCHEMBL4543548 | 0.86 | PIK3CB (0.44) | PIK3CBABCB1HRH1 | |
| SCHEMBL16798456 | 0.86 | PIK3CB (0.42) | PIK3CBABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105254634-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives useful in the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-109729716-B | PI3K inhibitor combination | 拜耳制药股份公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-105934256-B | PI3K inhibitor combination | 拜耳制药股份公司 | 2019-12-27 | — | — | CN | disclosed |
| EP-2638044-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638045-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638043-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062745-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062748-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062743-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |